Exhibitors Search
OncoLab Co., Ltd.
|
Exhibition
|
|
|---|---|
|
Booth no.
|
A60 |
|
Country
|
Korea, South |
|
Address
|
194-25, Osongsaengmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea |
|
Tel
|
<02-788-7400 |
|
Exhibits
|
ANGel (항체, 저분자약물 제형 및 전달체) |
|
Company Type
|
Exhibitor Information
OncoLaB is a deep-tech biotech venture developing ANGel, a next-generation precision drug formulation and delivery platform. ANGel is designed to simultaneously enhance the targetability, efficacy, and sustainability of cancer therapeutics.
Founded in May 2024 by Dr. Jongseong Kim, a scientist with over 20 years of expertise in bioadaptive nanogels and immunology, OncoLaB has rapidly established itself as a global oncology innovator.
Key Milestones:
Secured $500K seed investment
Selected for the Deep Tech TIPS program by the Ministry of SMEs and Startups ($1.5M in funding)
Awarded a TIPS follow-up grant ($200K in funding)
With triple-negative breast cancer (TNBC) as its lead indication, OncoLaB is building a scalable oncology platform with expansion into other hard-to-treat solid tumors, including prostate cancer and beyond.
Exhibit/Technology Introduction (General)
ANGel (Antibody Conjugated NanoGel)
Individual Exhibit/Technology Introduction (Detailed)
-
Product Name : ANGel (Antibody Conjugated NanoGel)A hydrogel-based microparticle drug delivery system that conjugates antibodies on the surface and loads small-molecule drugs inside, administered subcutaneously at the tumor site to provide sustained release for therapeutic treatment
KYUNGYON EXHIBITION CORP.